Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alexander Landfield

Neurology Winchester, KY Medical Doctor

NPI 1447451463 CMS profile 110607

225 Hospital Dr Ste 210, Winchester, KY 40391

Open in the dashboard

General payments

$6,912

525 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexander Landfield of Winchester, KY is reported in the CMS Open Payments database as having received $6,912 across 525 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,890 132
2024 General $2,089 130
2023 General $1,536 132
2022 General $925 88
2021 General $337 34
2020 General $42 3
2019 General $92 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexander Landfield
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Alexander Landfield were reported at $1,890. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Alexander Landfield Neurology median Middle half National median
2019 $92 $474 $118–$2,177 $163
2020 $42 $367 $82–$2,309 $114
2021 $337 $438 $104–$2,547 $132
2022 $925 $442 $103–$2,388 $149
2023 $1,536 $464 $119–$2,312 $160
2024 $2,089 $468 $119–$2,323 $164
2025 $1,890 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,755 145 payments
  2. Pfizer Inc. $1,483 142 payments
  3. Novartis Pharmaceuticals Corporation $637 36 payments
  4. Lilly USA, LLC $432 26 payments
  5. Teva Pharmaceuticals USA, Inc. $411 19 payments
  6. Biohaven Pharmaceutical Holding Company Ltd. $346 46 payments
  7. Neurelis, Inc. $260 14 payments
  8. Impel Pharmaceuticals Inc. $131 19 payments
  9. UCB, Inc. $122 5 payments
  10. Genentech USA, Inc. $116 6 payments
  11. Other $1,218 67 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,912 525 payments
Products named General payments · program years 2019–2025
  1. NURTEC ODT Pain $1,438 139 payments
  2. ZAVZPRET $1,223 116 payments
  3. QULIPTA $1,170 89 payments
  4. UBRELVY $1,008 85 payments
  5. KESIMPTA $510 30 payments
  6. NURTEC ODT Primary Care $428 50 payments
  7. EMGALITY $310 17 payments
  8. VALTOCO $260 14 payments
  9. Austedo XR $201 8 payments
  10. AJOVY $192 10 payments
  11. Other $2,580 176 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 88 drugs

Part D claims

6,768

Median for Neurology: 833

Drug cost

$1,932,127

Median for Neurology: $202,670

Branded share of claims

28.7%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 26 $514,102
Kesimpta Pen Ofatumumab Brand 31 $298,803
Nurtec Odt Rimegepant Sulfate Brand 137 $215,994
Qulipta Atogepant Brand 129 $158,810
Emgality Pen Galcanezumab-Gnlm Brand 174 $150,455
Aimovig Autoinjector Erenumab-Aooe Brand 132 $112,834
Eliquis Apixaban Brand 75 $66,057
Ubrelvy Ubrogepant Brand 49 $56,293
Trudhesa Dihydroergotamine Mesylate Brand 12 $48,665
Emgality Syringe Galcanezumab-Gnlm Brand 50 $43,774

The 10 drugs with the highest cost, of 88 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$94,490

Medicare's payments for the services billed

Medicare patients

447

Average age 73

Services billed

5,410

263 women, 184 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 40%
Ischemic heart disease 38%
Chronic kidney disease 31%
Depression 30%
COPD 29%
Alzheimer's or dementia 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $392
$392 129 —
NURTEC ODT
  • PFIZER INC. $248
$248 137 —
ZAVZPRET
  • PFIZER INC. $207
$207 — —
KESIMPTA
  • Novartis Pharmaceuticals Corporation $168
$168 31 —
UBRELVY
  • AbbVie, Inc. $143
$143 49 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

525 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record